secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2026-04-16T23:59:59+00:00
Accession:  0001104659-26-044028
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 1.02, 2.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

MeiraGTx acquires bota-vec gene therapy from Janssen for XLRP treatment
-----------------------------------------------------------------------

- MeiraGTx paid $25M upfront to Janssen for bota-vec, with a potential $50M milestone upon US approval and $250M sales threshold.
- Phase 3 LUMEOS trial showed 40% of treated patients improved in ≥2 endpoints vs 0% in control.
- MeiraGTx intends to file BLA and MAA in US, EU, and Japan for bota-vec, targeting potential launch in 2027.
- JJDC, Johnson & Johnson investment arm, owns >5% of MeiraGTx shares and agreed to 12-month lock-up.
- Estimated >20,000 XLRP patients in US and EU, with potential peak market of $1.7B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/0001104659-26-044028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000110465926044028/mgtx-20260415x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer